{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:39:38Z","timestamp":1780519178898,"version":"3.54.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T00:00:00Z","timestamp":1703548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T00:00:00Z","timestamp":1703548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s11154-023-09869-3","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T01:01:45Z","timestamp":1703552505000},"page":"505-512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cognition and psychological wellbeing in hypopituitary patients"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5066-871X","authenticated-orcid":false,"given":"Syed Ali","family":"Imran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,26]]},"reference":[{"key":"9869_CR1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1017\/cjn.2015.301","volume":"43","author":"K Al-Dahmani","year":"2016","unstructured":"Al-Dahmani K, Mohammad S, Imran F, et al. Sellar masses: an epidemiological study. Can J Neurol Sci. 2016;43:291\u20137. https:\/\/doi.org\/10.1017\/cjn.2015.301.","journal-title":"Can J Neurol Sci"},{"key":"9869_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-16-0041","volume":"175","author":"SA Imran","year":"2016","unstructured":"Imran SA, Yip CE, Papneja N, et al. Analysis and natural history of pituitary incidentalomas. Eur J Endocrinol. 2016;175:1\u20139. https:\/\/doi.org\/10.1530\/EJE-16-0041.","journal-title":"Eur J Endocrinol"},{"key":"9869_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4:173\u201382. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3064.","journal-title":"JAMA Oncol"},{"key":"9869_CR4","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1046\/j.1365-2265.2001.01406.x","volume":"55","author":"M Regal","year":"2001","unstructured":"Regal M, P\u00e1ramo C, Sierra SM, et al. Prevalence and incidence of hypopituitarism in an adult caucasian population in northwestern Spain. Clin Endocrinol. 2001;55:735\u201340. https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01406.x.","journal-title":"Clin Endocrinol"},{"key":"9869_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12020-016-1159-3","volume":"56","author":"S Jasim","year":"2017","unstructured":"Jasim S, Alahdab F, Ahmed AT, et al. Mortality in adults with hypopituitarism: a systematic review and meta-analysis. Endocrine. 2017;56:33\u201342. https:\/\/doi.org\/10.1007\/s12020-016-1159-3.","journal-title":"Endocrine"},{"key":"9869_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2165\/00019053-200017060-00008","volume":"17","author":"C Ehrnborg","year":"2000","unstructured":"Ehrnborg C, Hakkaart-Van Roijen L, et al. Cost of Illness in adult patients with hypopituitarism. PharmacoEconomics. 2000;17:621\u20138. https:\/\/doi.org\/10.2165\/00019053-200017060-00008.","journal-title":"PharmacoEconomics"},{"key":"9869_CR7","doi-asserted-by":"publisher","first-page":"E392","DOI":"10.1210\/jc.2010-1253","volume":"95","author":"J Tiemensma","year":"2010","unstructured":"Tiemensma J, Biermasz NR, van der Mast RC, et al. Increased psychopathology and maladaptive personality traits, but normal cognitive functioning, in patients after long-term cure of acromegaly. J Clin Endocrinol Metab. 2010;95:E392\u2013402.","journal-title":"J Clin Endocrinol Metab"},{"key":"9869_CR8","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1530\/EJE-22-0263","volume":"187","author":"R Pivonello","year":"2022","unstructured":"Pivonello R, Auriemma RS, Delli Veneri A, et al. Global psychological assessment with the evaluation of life and sleep quality and sexual and cognitive function in a large number of patients with acromegaly: a cross-sectional study. Eur J Endocrinol. 2022;187:823\u201345. https:\/\/doi.org\/10.1530\/EJE-22-0263.","journal-title":"Eur J Endocrinol"},{"key":"9869_CR9","doi-asserted-by":"publisher","first-page":"5325","DOI":"10.1210\/jc.2019-01054","volume":"104","author":"LHA Broersen","year":"2019","unstructured":"Broersen LHA, Andela CD, Dekkers OM, et al. Improvement but no normalization of quality of life and cognitive functioning after treatment of Cushing Syndrome. J Clin Endocrinol Metab. 2019;104:5325\u201337. https:\/\/doi.org\/10.1210\/jc.2019-01054.","journal-title":"J Clin Endocrinol Metab"},{"key":"9869_CR10","doi-asserted-by":"publisher","first-page":"E129","DOI":"10.1210\/jc.2010-0512","volume":"95","author":"J Tiemensma","year":"2010","unstructured":"Tiemensma J, Biermasz NR, Middelkoop HA, et al. Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing\u2019s Disease. J Clin Endocrinol Metab. 2010;95:E129\u2013141. https:\/\/doi.org\/10.1210\/jc.2010-0512.","journal-title":"J Clin Endocrinol Metab"},{"key":"9869_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1530\/EJE-07-0259","volume":"157","author":"M Kars","year":"2007","unstructured":"Kars M, van der Klaauw AA, Onstein CS, et al. Quality of life is decreased in female patients treated for microprolactinoma. Eur J Endocrinol. 2007;157:133\u20139. https:\/\/doi.org\/10.1530\/EJE-07-0259.","journal-title":"Eur J Endocrinol"},{"key":"9869_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1530\/EJE-08-0896","volume":"160","author":"C Sievers","year":"2009","unstructured":"Sievers C, Ising M, Pfister H, et al. Personality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and age- and gender-matched controls. Eur J Endocrinol. 2009;160:367\u201373. https:\/\/doi.org\/10.1530\/EJE-08-0896.","journal-title":"Eur J Endocrinol"},{"key":"9869_CR13","doi-asserted-by":"publisher","first-page":"e76562","DOI":"10.1371\/journal.pone.0076562","volume":"8","author":"G Zada","year":"2013","unstructured":"Zada G, Kintz N, Pulido M, et al. Prevalence of neurobehavioral, social, and emotional dysfunction in patients treated for childhood craniopharyngioma: a systematic literature review. PLoS ONE. 2013;8:e76562. https:\/\/doi.org\/10.1371\/journal.pone.0076562.","journal-title":"PLoS ONE"},{"key":"9869_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1530\/EJE-15-0888","volume":"174","author":"SA Imran","year":"2016","unstructured":"Imran SA, Tiemensma J, Kaiser SM, et al. Morphometric changes correlate with poor psychological outcomes in patients with acromegaly. Eur J Endocrinol. 2016;174:41\u201350. https:\/\/doi.org\/10.1530\/EJE-15-0888.","journal-title":"Eur J Endocrinol"},{"key":"9869_CR15","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.3390\/jcm12062283","volume":"12","author":"J Chen","year":"2023","unstructured":"Chen J, Xiang Z, Zhang Z, et al. Cognitive dysfunction, an increasingly valued long-term impairment in acromegaly. J Clin Med. 2023;12:2283. https:\/\/doi.org\/10.3390\/jcm12062283.","journal-title":"J Clin Med"},{"key":"9869_CR16","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1210\/clinem\/dgab079","volume":"106","author":"D Bengtsson","year":"2021","unstructured":"Bengtsson D, Ragnarsson O, Berinder K, et al. Psychotropic Drugs in patients with Cushing\u2019s Disease before diagnosis and at long-term follow-up: a nationwide study. J Clin Endocrinol Metab. 2021;106:1750\u201360. https:\/\/doi.org\/10.1210\/clinem\/dgab079.","journal-title":"J Clin Endocrinol Metab"},{"key":"9869_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11102-020-01089-1","volume":"24","author":"M van der Meulen","year":"2021","unstructured":"van der Meulen M, Zamanipoor Najafabadi AH, Lobatto DJ, et al. Healthcare utilization and costs among prolactinoma patients: a cross-sectional study and analysis of determinants. Pituitary. 2021;24:79\u201395. https:\/\/doi.org\/10.1007\/s11102-020-01089-1.","journal-title":"Pituitary"},{"key":"9869_CR18","doi-asserted-by":"publisher","first-page":"22565","DOI":"10.1038\/s41598-022-26331-7","volume":"12","author":"A Bala","year":"2022","unstructured":"Bala A, Dziedzic T, Olejnik A, et al. Attention and working memory in patients with prolactinomas: a case-control study. Sci Rep. 2022;12:22565. https:\/\/doi.org\/10.1038\/s41598-022-26331-7.","journal-title":"Sci Rep"},{"key":"9869_CR19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s12020-013-0106-9","volume":"46","author":"CG Yedinak","year":"2014","unstructured":"Yedinak CG, Fleseriu M. Self-perception of cognitive function among patients with active acromegaly, controlled acromegaly, and non-functional pituitary adenoma: a pilot study. Endocrine. 2014;46:585\u201393. https:\/\/doi.org\/10.1007\/s12020-013-0106-9.","journal-title":"Endocrine"},{"key":"9869_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1365-2265.2010.03947.x","volume":"74","author":"P Brummelman","year":"2011","unstructured":"Brummelman P, Elderson MF, Dullaart RP, et al. Cognitive functioning in patients treated for nonfunctioning pituitary macroadenoma and the effects of pituitary radiotherapy. Clin Endocrinol. 2011;74:481\u20137. https:\/\/doi.org\/10.1111\/j.1365-2265.2010.03947.x.","journal-title":"Clin Endocrinol"},{"key":"9869_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11060-017-2492-y","volume":"134","author":"AS Fournier-Goodnight","year":"2017","unstructured":"Fournier-Goodnight AS, Ashford JM, Merchant TE, et al. Neurocognitive functioning in pediatric craniopharyngioma: performance before treatment with proton therapy. J Neurooncol. 2017;134:97\u2013105. https:\/\/doi.org\/10.1007\/s11060-017-2492-y.","journal-title":"J Neurooncol"},{"key":"9869_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3171\/2022.12.PEDS22367","volume":"31","author":"G Aldave","year":"2023","unstructured":"Aldave G, Okcu MF, Chintagumpala M, et al. Comparison of neurocognitive and quality-of-life outcomes in pediatric craniopharyngioma patients treated with partial resection and radiotherapy versus gross-total resection only. J Neurosurg Pediatr. 2023;31:453\u201362. https:\/\/doi.org\/10.3171\/2022.12.PEDS22367.","journal-title":"J Neurosurg Pediatr"},{"key":"9869_CR23","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s11102-021-01131-w","volume":"24","author":"TNA Slagboom","year":"2021","unstructured":"Slagboom TNA, Deijen JB, Van Bunderen CC, et al. Psychological well-being and Illness perceptions in patients with hypopituitarism. Pituitary. 2021;24:542\u201354. https:\/\/doi.org\/10.1007\/s11102-021-01131-w.","journal-title":"Pituitary"},{"key":"9869_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-022-01672-3","author":"C Mahajan","year":"2023","unstructured":"Mahajan C, Prabhakar H, Bilotta F. Endocrine dysfunction after traumatic Brain Injury: an ignored clinical syndrome? Neurocrit Care. 2023. https:\/\/doi.org\/10.1007\/s12028-022-01672-3.","journal-title":"Neurocrit Care"},{"key":"9869_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1677\/JOE-10-0126","volume":"207","author":"JA Wass","year":"2010","unstructured":"Wass JA, Reddy R. Growth hormone and memory. J Endocrinol. 2010;207:125\u20136. https:\/\/doi.org\/10.1677\/JOE-10-0126.","journal-title":"J Endocrinol"},{"key":"9869_CR26","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1089\/neu.2012.2705","volume":"30","author":"OK Moreau","year":"2013","unstructured":"Moreau OK, Cortet-Rudelli C, Yollin E. Growth hormone replacement therapy in patients with traumatic brain injury. J Neurotrauma. 2013;30:998\u20131006. https:\/\/doi.org\/10.1089\/neu.2012.2705.","journal-title":"J Neurotrauma"},{"key":"9869_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.yhbeh.2004.11.015","volume":"47","author":"LI Arwert","year":"2005","unstructured":"Arwert LI, Deijen JB, M\u00fcller M, et al. Long-term growth hormone treatment preserves GH-induced memory and mood improvements: a 10-year follow-up study in GH-deficient adult men. Horm Behav. 2005;47:343\u20139. https:\/\/doi.org\/10.1016\/j.yhbeh.2004.11.015.","journal-title":"Horm Behav"},{"key":"9869_CR28","doi-asserted-by":"publisher","first-page":"1082449","DOI":"10.3389\/fnins.2023.1082449","volume":"17","author":"DG Blackmore","year":"2023","unstructured":"Blackmore DG, Waters MJ. The multiple roles of GH in neural ageing and injury. Front Neurosci. 2023;17:1082449. https:\/\/doi.org\/10.3389\/fnins.2023.1082449.","journal-title":"Front Neurosci"},{"key":"9869_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000184753","volume":"45","author":"F Nyberg","year":"1996","unstructured":"Nyberg F, Burman P. Growth hormone and its receptors in the central nervous system - location and functional significance. Horm Res. 1996;45:18\u201322. https:\/\/doi.org\/10.1159\/000184753.","journal-title":"Horm Res"},{"key":"9869_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/s0304-3940(00)00830-2","volume":"281","author":"JR Castro","year":"2000","unstructured":"Castro JR, Costoya JA, Gallego R, et al. Expression of growth hormone receptor in the human brain. Neurosci Letts. 2000;281:147\u201350. https:\/\/doi.org\/10.1016\/s0304-3940(00)00830-2.","journal-title":"Neurosci Letts"},{"key":"9869_CR31","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1210\/jcem.78.3.8126150","volume":"78","author":"M Mercado","year":"1994","unstructured":"Mercado M, D\u00e1vila N, McLeod JF, et al. Distribution of growth hormone receptor messenger ribonucleic acid containing and lacking exon 3 in human tissues. J Clin Endocrinol Metab. 1994;78:731\u20135. https:\/\/doi.org\/10.1210\/jcem.78.3.8126150.","journal-title":"J Clin Endocrinol Metab"},{"key":"9869_CR32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/0006-8993(91)91485-j","volume":"546","author":"Z Lai","year":"1991","unstructured":"Lai Z, Emtner M, Roos P, et al. Characterization of putative growth hormone receptors in human choroid plexus. Brain Res. 1991;546:222\u20136. https:\/\/doi.org\/10.1016\/0006-8993(91)91485-j.","journal-title":"Brain Res"},{"key":"9869_CR33","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/0006-8993(93)90114-3","volume":"621","author":"Z Lai","year":"1993","unstructured":"Lai Z, Roos P, Zhai Q, et al. Age-related reduction of human growth hormone binding sites in the human brain. Brain Res. 1993;621:260\u20136. https:\/\/doi.org\/10.1016\/0006-8993(93)90114-3.","journal-title":"Brain Res"},{"key":"9869_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000126813","volume":"61","author":"JO Johansson","year":"1995","unstructured":"Johansson JO, Larson G, Andersson M, et al. Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters. Neuroendocrinol. 1995;61:57\u201366. https:\/\/doi.org\/10.1159\/000126813.","journal-title":"Neuroendocrinol"},{"key":"9869_CR35","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1046\/j.1365-2265.1996.617439.x","volume":"44","author":"P Burman","year":"1996","unstructured":"Burman P, Hetta J, Wide L, et al. Growth hormone treatment affects brain neurotransmitters and thyroxine. Clin Endocrinol. 1996;44:319\u201324. https:\/\/doi.org\/10.1046\/j.1365-2265.1996.617439.x.","journal-title":"Clin Endocrinol"},{"key":"9869_CR36","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1210\/jcem-31-2-230","volume":"31","author":"JA Linfoot","year":"1970","unstructured":"Linfoot JA, Garcia JF, Wei W, et al. Human growth hormone levels in cerebrospinal fluid. J Clin Endocrinol. 1970;31:230\u20132. https:\/\/doi.org\/10.1210\/jcem-31-2-230.","journal-title":"J Clin Endocrinol"},{"key":"9869_CR37","first-page":"205","volume":"17","author":"M Coculescu","year":"1979","unstructured":"Coculescu M, Simionescu L, Constantinovici A, et al. High level of human growth hormone (HGH) in cerebrospinal fluid patients with pituitary tumors. Endocrinologie. 1979;17:205\u201311.","journal-title":"Endocrinologie"},{"key":"9869_CR38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1515\/jpem.1999.12.2.113","volume":"12","author":"M Coculescu","year":"1999","unstructured":"Coculescu M. Blood-brain barrier for human growth hormone and insulin-like growth factor-1. J Ped Endocrinol Metab. 1999;12:113\u201324. https:\/\/doi.org\/10.1515\/jpem.1999.12.2.113.","journal-title":"J Ped Endocrinol Metab"},{"key":"9869_CR39","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/s0026-0495(98)90007-5","volume":"37","author":"KR Duffy","year":"1988","unstructured":"Duffy KR, Pardridge WM, Rosenfeld RG. Human blood-brain barrier insulin-like growth factor receptor. Metabolism. 1988;37:136\u201340. https:\/\/doi.org\/10.1016\/s0026-0495(98)90007-5.","journal-title":"Metabolism"},{"key":"9869_CR40","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/0140-6736(93)92975-y","volume":"342","author":"P Burman","year":"1993","unstructured":"Burman P, Hetta J, Karlsson A. Effects of growth hormone on brain neurotransmitters. Lancet. 1993;342:1492\u20133. https:\/\/doi.org\/10.1016\/0140-6736(93)92975-y.","journal-title":"Lancet"},{"key":"9869_CR41","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000125320","volume":"51","author":"C Astr\u00f6m","year":"1990","unstructured":"Astr\u00f6m C, Lindholm J. Growth hormone-deficient young adults have decreased deep sleep. Neuroendocrinol. 1990;51:82\u20134. https:\/\/doi.org\/10.1159\/000125320.","journal-title":"Neuroendocrinol"},{"key":"9869_CR42","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/j.1365-2265.1990.tb03886.x","volume":"33","author":"C Astr\u00f6m","year":"1990","unstructured":"Astr\u00f6m C, Pedersen SA, Lindholm J. The influence of growth hormone on sleep in adults with growth hormone deficiency. Clin Endocrinol. 1990;33:495\u2013500. https:\/\/doi.org\/10.1111\/j.1365-2265.1990.tb03886.x.","journal-title":"Clin Endocrinol"},{"key":"9869_CR43","unstructured":"Garcia JM, Merriam GR, Kargi AY. Growth hormone in aging. https:\/\/endotext.org\/wp-content\/uploads\/pdfs\/growth-hormone-in-aging.pdf."},{"key":"9869_CR44","doi-asserted-by":"publisher","first-page":"229","DOI":"10.31887\/DCNS.2001.3.3\/mvvitiello","volume":"3","author":"MV Vitiello","year":"2001","unstructured":"Vitiello MV, Schwartz RS, Moe KE, et al. Treating age-related changes in somatotrophic hormones, sleep, and cognition. Dialogues Clin Neurosci. 2001;3:229\u201336. https:\/\/doi.org\/10.31887\/DCNS.2001.3.3\/mvvitiello.","journal-title":"Dialogues Clin Neurosci"},{"key":"9869_CR45","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1210\/jc.2007-0297","volume":"92","author":"M Slawik","year":"2007","unstructured":"Slawik M, Klawitter B, Meiser E, et al. Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine. J Clin Endocrinol Metab. 2007;92:4115\u201322. https:\/\/doi.org\/10.1210\/jc.2007-0297.","journal-title":"J Clin Endocrinol Metab"},{"key":"9869_CR46","doi-asserted-by":"publisher","first-page":"10535","DOI":"10.1016\/j.neuint.2022.105305","volume":"155","author":"M Naicker","year":"2022","unstructured":"Naicker M, Naidoo S. Cellular and molecular distribution of thyroid-specific proteins, thyroid-stimulating hormone receptor (TSH-R) and thyroglobulin (TG) in the central nervous system. Neurochem Int. 2022;155:10535. https:\/\/doi.org\/10.1016\/j.neuint.2022.105305.","journal-title":"Neurochem Int"},{"key":"9869_CR47","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jns.2010.11.027","volume":"302","author":"K Moodley","year":"2011","unstructured":"Moodley K, Botha J, Raidoo DM, et al. Immuno-localization of anti-thyroid antibodies in adult human cerebral cortex. J Neurol Sci. 2011;302:114\u20137.","journal-title":"J Neurol Sci"},{"issue":"4","key":"9869_CR48","first-page":"4","volume":"1","author":"DR Spiegel","year":"2017","unstructured":"Spiegel DR, Nelson AB, Lieb DC, et al. A case of psychosis in a patient with secondary adrenal insufficiency: a possible etiological role of a hypocortisolemic-induced increase in proinflammatory cytokines. Innov Clin Neurosci. 2017;1(4):4\u201310.","journal-title":"Innov Clin Neurosci"},{"key":"9869_CR49","doi-asserted-by":"publisher","first-page":"286","DOI":"10.14740\/jocmr2041w","volume":"7","author":"N Jessani","year":"2015","unstructured":"Jessani N, Jehangir W, Behman D, et al. Secondary adrenal insufficiency: an overlooked cause of hyponatremia. J Clin Med Res. 2015;7:286\u20138. https:\/\/doi.org\/10.14740\/jocmr2041w.","journal-title":"J Clin Med Res"},{"key":"9869_CR50","doi-asserted-by":"publisher","first-page":"6664","DOI":"10.3390\/ijms24076664","volume":"24","author":"DD Markov","year":"2023","unstructured":"Markov DD, Dolotov OV, Grivennikov IA. The Melanocortin System: a promising target for the development of new antidepressant Drugs. Int J Mol Sci. 2023;24:6664. https:\/\/doi.org\/10.3390\/ijms24076664.","journal-title":"Int J Mol Sci"},{"key":"9869_CR51","doi-asserted-by":"publisher","first-page":"144949","DOI":"10.1016\/j.gene","volume":"757","author":"NNA Berruien","year":"2020","unstructured":"Berruien NNA, Smith CL. Emerging roles of melanocortin receptor accessory proteins (MRAP and MRAP2) in physiology and pathophysiology. Gene. 2020;757:144949. https:\/\/doi.org\/10.1016\/j.gene.","journal-title":"Gene"},{"key":"9869_CR52","doi-asserted-by":"publisher","first-page":"742","DOI":"10.3389\/fneur.2017.00742","volume":"8","author":"S Yao","year":"2018","unstructured":"Yao S, Song J, Gao J, et al. Cognitive function and serum hormone levels are associated with gray matter decline in female patients with prolactinomas. Front Neurol. 2018;8:742. https:\/\/doi.org\/10.3389\/fneur.2017.00742.","journal-title":"Front Neurol"},{"key":"9869_CR53","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3389\/fneur.2021.638851","volume":"14","author":"J Song","year":"2020","unstructured":"Song J, Cao C, Wang Y, et al. Response activation and inhibition in patients with prolactinomas: an electrophysiological study. Front Hum Neurosci. 2020;14:170. https:\/\/doi.org\/10.3389\/fneur.2021.638851.","journal-title":"Front Hum Neurosci"},{"key":"9869_CR54","doi-asserted-by":"publisher","unstructured":"Rajkumar RP. Prolactin and psychopathology in schizophrenia: A literature review and reappraisal. Schizophrenia Res Treat. 2014; 2014: 175360. https:\/\/doi.org\/10.1155\/2014\/175360.","DOI":"10.1155\/2014\/175360"},{"key":"9869_CR55","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11154-015-9322-3","volume":"16","author":"G Rastrelli","year":"2015","unstructured":"Rastrelli G, Corona G, Maggi M. The role of prolactin in andrology: what is new? Rev Endocr Metab Disord. 2015;16:233\u201348. https:\/\/doi.org\/10.1007\/s11154-015-9322-3.","journal-title":"Rev Endocr Metab Disord"},{"key":"9869_CR56","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1111\/and.12199","volume":"46","author":"L La\u0161ait\u0117","year":"2014","unstructured":"La\u0161ait\u0117 L, Ceponis J, Preik\u0161a RT, et al. Impaired emotional state, quality of life and cognitive functions in young hypogonadal men. Andrologia. 2014;46:1107\u201312. https:\/\/doi.org\/10.1111\/and.12199.","journal-title":"Andrologia"},{"key":"9869_CR57","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.3390\/jcm10122622","volume":"10","author":"M Ka\u0142u\u017cna","year":"2021","unstructured":"Ka\u0142u\u017cna M, Kompf P, Rabijewski M, et al. Reduced quality of life and sexual satisfaction in isolated hypogonadotropic hypogonadism. J Clin Med. 2021;10:2622. https:\/\/doi.org\/10.3390\/jcm10122622.","journal-title":"J Clin Med"},{"key":"9869_CR58","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1210\/endrev\/bnab043","volume":"43","author":"S Federici","year":"2022","unstructured":"Federici S, Goggi G, Quinton R, et al. New and consolidated therapeutic options for pubertal induction in hypogonadism: In-depth review of the literature. Endocr Rev. 2022;43:824\u201351. https:\/\/doi.org\/10.1210\/endrev\/bnab043.","journal-title":"Endocr Rev"},{"key":"9869_CR59","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.yhbeh.2015.06.020","volume":"76","author":"JA Blair","year":"2015","unstructured":"Blair JA, Bhatta S, McGee H, et al. Luteinizing hormone: evidence for direct action in the CNS. Horm Behav. 2015;76:57\u201362. https:\/\/doi.org\/10.1016\/j.yhbeh.2015.06.020.","journal-title":"Horm Behav"},{"key":"9869_CR60","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.bbrc.2020.03.039","volume":"525","author":"WK Bi","year":"2020","unstructured":"Bi WK, Luan SS, Wang J, et al. FSH signaling is involved in affective disorders. Biochem Biophys Res Commun. 2020;525:915\u201320. https:\/\/doi.org\/10.1016\/j.bbrc.2020.03.039.","journal-title":"Biochem Biophys Res Commun"},{"key":"9869_CR61","doi-asserted-by":"publisher","first-page":"5987","DOI":"10.1210\/jc.2004-1058","volume":"89","author":"A Agha","year":"2004","unstructured":"Agha A, Thornton E, O\u2019Kelly P. Posterior pituitary dysfunction after traumatic brain injury. J Clin Endocrinol Metab. 2004;89:5987\u201392. https:\/\/doi.org\/10.1210\/jc.2004-1058.","journal-title":"J Clin Endocrinol Metab"},{"key":"9869_CR62","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1001\/archpsyc.55.8.708","volume":"55","author":"EF Coccaro","year":"1998","unstructured":"Coccaro EF, Kavoussi RJ, Hauger RL, et al. Cerebrospinal fluid vasopressin levels. Arch Gen Psychiatry. 1998;55:708\u201314. https:\/\/doi.org\/10.1001\/archpsyc.55.8.708.","journal-title":"Arch Gen Psychiatry"},{"key":"9869_CR63","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1111\/bph.15481","volume":"179","author":"M Rae","year":"2022","unstructured":"Rae M, Lemos Duarte M, Gomes I. Oxytocin and vasopressin: signalling, behavioural modulation and potential therapeutic effects. Br J Pharmacol. 2022;179:1544\u201364. https:\/\/doi.org\/10.1111\/bph.15481.","journal-title":"Br J Pharmacol"},{"key":"9869_CR64","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.3390\/jcm9113682","volume":"9","author":"MJ Brownstein","year":"2020","unstructured":"Brownstein MJ, Simon NG, Long JD, et al. Safety and tolerability of SRX246, a vasopressin 1a antagonist, in irritable Huntington\u2019s Disease patients-a randomized phase 2 clinical trial. J Clin Med. 2020;9:3682. https:\/\/doi.org\/10.3390\/jcm9113682.","journal-title":"J Clin Med"},{"key":"9869_CR65","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3389\/fnsys.2013.00100","volume":"12","author":"RJ Lee","year":"2013","unstructured":"Lee RJ, Coccaro EF, Cremers H, et al. A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study. Front Syst Neurosci. 2013;12:7: 100. https:\/\/doi.org\/10.3389\/fnsys.2013.00100.","journal-title":"Front Syst Neurosci"},{"key":"9869_CR66","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S2213-8587(22)00219-4","volume":"10","author":"C Atila","year":"2022","unstructured":"Atila C, Loughrey PB, Garrahy A, et al. Central Diabetes insipidus from a patient\u2019s perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey. Lancet Diabetes Endocrinol. 2022;10:700\u20139. https:\/\/doi.org\/10.1016\/S2213-8587(22)00219-4.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"9869_CR67","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S2213-8587(23)00120-1","volume":"11","author":"C Atila","year":"2023","unstructured":"Atila C, Holze F, Murugesu R, Rommers N, et al. Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central Diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial. Lancet Diab Endocrinol. 2023;11:454\u201364. https:\/\/doi.org\/10.1016\/S2213-8587(23)00120-1.","journal-title":"Lancet Diab Endocrinol"},{"key":"9869_CR68","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S2213-8587(23)00120-1","volume":"19","author":"JG Verbalis","year":"2023","unstructured":"Verbalis JG. Oxytocin deficiency \u2013 a \u2018new\u2019 human disorder? Nat Revs Endocrinol. 2023;19:505\u20136. https:\/\/doi.org\/10.1016\/S2213-8587(23)00120-1.","journal-title":"Nat Revs Endocrinol"},{"key":"9869_CR69","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.psyneuen.2009.06.002","volume":"34","author":"R Lee","year":"2009","unstructured":"Lee R, Ferris C, Van de Kar LD, Coccaro EF. Cerebrospinal fluid oxytocin, life history of aggression, and personality disorder. Psychoneuroendocrinol. 2009;34:1567\u201373. https:\/\/doi.org\/10.1016\/j.psyneuen.2009.06.002.","journal-title":"Psychoneuroendocrinol"},{"key":"9869_CR70","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.psyneuen.2011.07.016","volume":"37","author":"J Jokinen","year":"2012","unstructured":"Jokinen J, Chatzittofis A, Hellstr\u00f6m C, et al. Low CSF oxytocin reflects high intent in Suicide attempters. Psychoneuroendocrinol. 2012;37:482\u201390. https:\/\/doi.org\/10.1016\/j.psyneuen.2011.07.016.","journal-title":"Psychoneuroendocrinol"},{"key":"9869_CR71","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.psyneuen.2018.05.031","volume":"96","author":"SA Grace","year":"2018","unstructured":"Grace SA, Rossell SL, Heinrichs M, et al. Oxytocin and brain activity in humans: a systematic review and coordinate-based meta-analysis of functional MRI studies. Psychoneuroendocrinol. 2018;96:6\u201324. https:\/\/doi.org\/10.1016\/j.psyneuen.2018.05.031.","journal-title":"Psychoneuroendocrinol"},{"key":"9869_CR72","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1503\/jpn.130289","volume":"40","author":"R Wigton","year":"2015","unstructured":"Wigton R, Radua J, Allen P, et al. Neurophysiological effects of acute oxytocin administration: systematic review and meta-analysis of placebo-controlled imaging studies. J Psychiatry Neurosci. 2015;40:E1\u2013E22. https:\/\/doi.org\/10.1503\/jpn.130289.","journal-title":"J Psychiatry Neurosci"},{"key":"9869_CR73","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/ejendo\/lvad057","volume":"188","author":"DS Olsson","year":"2023","unstructured":"Olsson DS, Svensson M, Labori F, et al. Healthcare cost and survival in patients with non-functioning pituitary adenoma. Eur J Endocrinol. 2023;188:477\u201384. https:\/\/doi.org\/10.1093\/ejendo\/lvad057.","journal-title":"Eur J Endocrinol"},{"key":"9869_CR74","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S2213-8587(14)70142-1","volume":"3","author":"I Bancos","year":"2015","unstructured":"Bancos I, Hahner S, Tomlinson J, et al. Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol. 2015;3:216\u201326. https:\/\/doi.org\/10.1016\/S2213-8587(14)70142-1.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"9869_CR75","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1530\/EJE-14-0097","volume":"170","author":"G Mazziotti","year":"2014","unstructured":"Mazziotti G, Mormando M, Cristiano A, et al. Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. Eur J Endocrinol. 2014;170:893\u20139. https:\/\/doi.org\/10.1530\/EJE-14-0097.","journal-title":"Eur J Endocrinol"},{"key":"9869_CR76","doi-asserted-by":"publisher","unstructured":"Martel-Duguech LM, Jorgensen JOL, Korbonits M et al. ESE audit on management of Adult Growth Hormone Deficiency in clinical practice. Eur J Endocrinol. 2020: EJE-20-1180.R1. https:\/\/doi.org\/10.1530\/EJE-20-1180.","DOI":"10.1530\/EJE-20-1180"},{"key":"9869_CR77","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/ewjm.172.2.124","volume":"172","author":"J Turner","year":"2000","unstructured":"Turner J, Kelly B. Emotional dimensions of chronic Disease. West J Med. 2000;172:124\u20138. https:\/\/doi.org\/10.1136\/ewjm.172.2.124.","journal-title":"West J Med"},{"key":"9869_CR78","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s11102-017-0835","volume":"20","author":"AJ van der Lely","year":"2017","unstructured":"van der Lely AJ, Gomez R, Pleil A, et al. Development of ACRODAT((R)), a new software medical device to assess Disease activity in patients with acromegaly. Pituitary. 2017;20:692\u2013701. https:\/\/doi.org\/10.1007\/s11102-017-0835.","journal-title":"Pituitary"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-023-09869-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-023-09869-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-023-09869-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T07:22:39Z","timestamp":1717831359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-023-09869-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,26]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["9869"],"URL":"https:\/\/doi.org\/10.1007\/s11154-023-09869-3","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,26]]},"assertion":[{"value":"13 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}